Norbert Farkas April 11, 2022 Publications Access relevant diagnostics scientific publications – 2022 March Norbert Farkas April 11, 2022 Publications Exciting, selected scientific publications from the world of (digital) diagnostics from market access, health care systems, policy, and clinical value perspectives.
Guest User April 5, 2021 Access, Policy 3 interesting reimbursement, policy learnings in oncology diagnostics (EDL, liquid biopsy, breast cancer recurrence risk scores) Guest User April 5, 2021 Access, Policy 1. EGFR tests included for NSCLC in WHO’s third Essential Diagnostics List2. Germany has a liquid biopsy tariff for locally advanced or metastatic NSCLC3. Breast cancer recurrence risk scores: Oncotype DX first to be nationally reimbursed in Germany but others may soon join the game
